Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medytox Faces Botulinum Approval Cancellation Over Data Issues

But Korean Firm Pushes Back

Executive Summary

Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.

You may also be interested in...



Korea Botox Rivalry To Intensify After Meditoxin Measures

As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.

Medytox, Daewoong’s Botox Strain Dispute Set To Simmer Until Commission Decision

The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.

Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors

Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel